Premium
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia
Author(s) -
Pinto Duane S.,
Sperling Robert T.,
Tu Thomas M.,
Cohen David J.,
Carrozza Joseph P.
Publication year - 2003
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10393
Subject(s) - medicine , eptifibatide , lepirudin , abciximab , tirofiban , bivalirudin , percutaneous coronary intervention , discovery and development of direct thrombin inhibitors , direct thrombin inhibitor , heparin , conventional pci , heparin induced thrombocytopenia , clopidogrel , platelet , cardiology , thrombin , aspirin , myocardial infarction , dabigatran , warfarin , atrial fibrillation
We evaluated a combination therapy using glycoprotein IIb/IIIa receptor antagonism and direct thrombin inhibition in nine patients with heparin‐induced thrombocytopenia (HIT) undergoing 10 percutaneous coronary interventions (PCIs). In selected patients with HIT, the combination of a direct thrombin inhibitor, lepirudin, and abciximab, tirofiban, or eptifibatide appears to be a safe and effective anticoagulation strategy for PCI. Cathet Cardiovasc Intervent 2003;58:65–68. © 2003 Wiley‐Liss, Inc.